16.9 C
New York
Wednesday, May 25, 2022

Tonix Pharmaceuticals Holding Corp (TNXP) stock is up in the after-market. Here’s why

The stock of Tonix Pharmaceuticals Holding Corp (TNXP) closed the regular trading session at $0.2379, losing 5.93% from the previous trading session. During the last check, the stock of TNXP was up in the after-market. TNXP stock gained 1.3% to $0.241 in the after-market. The company declared the results for a study of TNX-102 SL 5.6 mg. Also, TNXP is going to take part in the 2022 virtual conference. Moreover, Toxic published the financial results for Q4 and FY21. The company also filed form 8-K with the SEC on 14 March 2022.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


Tonix Pharmaceuticals is a drug organization that spotlights reused drugs for focal sensory system conditions and in 2020 was additionally chasing after an antibody for COVID-19 and a biodefense project. The firm has a market cap of $118.06 million. TNXP is headquartered in Chatham, New Jersey, USA.


On 21 March 2022, TNXP released the out-turn of their study for TNX-102 SL 5.6 mg. NX-102 SL didn’t accomplish measurable importance on the essential endpoint of decreasing fibromyalgia everyday torment at 14th week contrasted with fake treatment in the Phase 3 study. 514 patients with FM (fibromyalgia) took part in the study. All members got TNX-102 SL 2.8 mg or fake treatment for the initial fourteen days. TNX-102 SL is in between the Phase 3 advancement for managing fibromyalgia. In December 2020, Tonix revealed promising outcomes from the Phase 3 investigation.

Moreover, on 22 March 2022, the firm declared that its CEO, Seth Lederman, will be a part of the 2022 virtual seminar, held by Maxim Group LLC. The seminar is going to be from 28 March 2022 to 30 March 2022.

Company Financials

On 14 March 2022, TNXP published the fiscal performance for Q4 and FY2021. The company reported the cost and expenses to be $68.8 million in FY21 versus $50.5 million in FY20. Moreover, the company had costs and expenses of $29.5 million in Q4 of FY21 compared to $17.02 million in Q4 of FY20.

Also, TNXP’s total loss increased by 82.8% to $92.2 million in FY21 as compared to $50.4 million in FY20. The company’s total loss in Q4 of FY21 was $29.5 million against $17.02 million in the same year-ago period.

Moreover, the loss of $0.26 and $0.07 per stock in Q4 and FY21, respectively.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles